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TranscriptionThe biologically most active vitamin D compound, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), inﬂuences
the status of inﬂammation by modulating the expression of several cytokine genes. In this study, we have
examined the mechanism of transcriptional regulation of interleukin 10 (IL-10) by 1α,25(OH)2D3 in
lipopolysaccharide (LPS)-treated human monocytes (THP-1). Quantitative PCR showed that IL-10 mRNA
expression was signiﬁcantly down-regulated (2.8-fold) during the ﬁrst 8 h of 1α,25(OH)2D3 treatment,
while after 48 h it was up-regulated (3-fold). Gel shift and quantitative chromatin immunoprecipitation
(ChIP) assays showed that the vitamin D receptor (VDR) binds in a cyclical fashion to a promoter region
1500–1700 bp upstream of the IL-10 transcription start site (TSS) containing two conserved VDR binding
sites. Targeting of VDR binding sites by enhancer speciﬁc duplex RNAs revealed that only the more distal
element is functional and chromosome conformation capture analysis suggested that this region loops 1α,25
(OH)2D3-dependently to the TSS. Quantitative ChIP and micrococcal nuclease assays also revealed 1α,25
(OH)2D3-dependent cyclical epigenetic changes and nucleosome remodeling at this promoter region. In
conclusion, in LPS-treated THP-1 cells the primary effect of 1α,25(OH)2D3 on IL-10 expression is down-
regulation, which is achieved via a cyclical recruitment of VDR to the promoter.itamin D3; 3C, chromosome
itation; DR, direct repeat; ER,
PS, lipopolysaccharide; MNase,
XR, retinoid X receptor; TSS,
or; VDR, vitamin D receptor;
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The biologically most active vitamin D compound, 1α,25(OH)2D3,
has besides its classical properties on regulation of serum calcium and
phosphorus levels and bone formation also an important role as a
modulator of immune responses. 1α,25(OH)2D3 regulates the
transcription of several cytokine genes, for example interleukin (IL)
2, 10 and 12 and interferon γ in T cells and dendritic cells [1–3]. The
role of 1α,25(OH)2D3 as a regulator of immune responses is further
underlined by the fact that the vitamin D receptor (VDR) is expressed
in antigen presenting cells [4,5] and that activated macrophages are
able to synthesize and secrete 1α,25(OH)2D3 [6].VDR binds as a heterodimer with the retinoid X receptor (RXR) to
speciﬁc genomic loci, so-called vitamin D response elements (VDREs),
within the regulative regions of primary 1α,25(OH)2D3 target genes.
This results in the activation or the repression of these genes. VDR–
RXR heterodimers can bind to VDREs that are formed by direct repeats
(DRs) of the hexameric consensus sequence RGKTCA (R=A or G,
K=G or T) with three or four intervening nucleotides (DR3 and DR4)
or by everted repeats (ERs) with six to nine spacing nucleotides (ER6
to ER9) [7–9]. Recent studies have suggested that the association of
VDR with regulatory regions of primary up-regulated 1α,25(OH)2D3
target gene is cyclic and that this cyclical behavior also mirrors to the
mRNA expression level [10–12]. So far only MYC is known as an
example of a primary down-regulated 1α,25(OH)2D3 target gene that
shows transcriptional cycling [13].
The 1α,25(OH)2D3-dependent repression of VDR target genes
appears to be mediated either through E-box type elements [14] or
via consensus VDREs [15–18]. The repression via E-box type elements
involves the association of VDR-interacting repressors (VDIRs),which in
turn recruit VDR–RXR complexes and other proteins needed for
transcriptional repression, such as the co-repressor NCoR [19,20].
However, the repression via consensus VDREs is still poorly understood.
IL-10 primarily dampens the immune response, since it is
produced mainly by regulatory T cells and macrophages and inhibits
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stimulatory proteins and major histocompatibility II complexes in
dendritic cells [21]. However, IL-10 also enhances B cell survival and
antibody production and thus it can also stimulate the immune
response. Thismay explain inconsistent reports on the effects of 1α,25
(OH)2D3 on IL-10 expression, some of which claimed repressive
effects [22–24] but others stimulatory results [25–28].
In this study, we focused on the primary effects of 1α,25(OH)2D3
on IL-10 expression and their mechanisms. Our data suggest that IL-10
is repressed during the ﬁrst 8 h after onset of 1α,25(OH)2D3
treatment in LPS-treated THP-1 cells. However, 48 h later IL-10
mRNA expression is clearly increased suggesting a secondary effect.
Highly similar, bidirectional effect of 1α,25(OH)2D3 on IL-10 expres-
sion could be observed also in primary monocytes. According to our
promoter targeting data the primary effect of 1α,25(OH)2D3 appears
to bemediated via an ER8-type VDRE located 1721–1701 bp upstream
of the TSS. Chromosome conformation capture (3C) analysis
suggested that this promoter region loops in a ligand- and time-
dependent fashion with the TSS of the IL-10 gene. Quantitative ChIP
assays revealed that the promoter region and the TSS recruit VDR, RXR
and the co-repressor NCoR in a cyclical fashion as well as markers of
active and repressed chromatin. This could be conﬁrmed by
assessment of nucleosome enrichment.
2. Material and methods
2.1. Cell culture
THP-1 human acute monocytic leukemia cells were maintained in
RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) and SW-480
human colon adenocarcinoma cell line was cultured in Dulbecco's
Modiﬁed Eagle Medium (DMEM). Both media contained 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 0.1 mg/ml streptomycin and
100 U/ml penicillin and culturing was in a humidiﬁed 95% air/5% CO2
incubator. Before use in experimental procedures, FBS was stripped
from lipophilic compounds, such as endogenous nuclear receptor
ligands, by stirring it with 5% activated charcoal (Sigma-Aldrich) for
3 h at room temperature. Charcoal was then removed by centrifuga-
tion, and the medium was sterilized by ﬁltration (0.2 μm pore size).
THP-1 and SW480 cells were maintained for experiments in phenol
red-free DMEM, supplemented with 5% charcoal-stripped FBS, 2 mM
L-glutamine, 0.1 mg/ml streptomycin and 100 U/ml penicillin. Prior
to RNA or chromatin extraction, the cells were treatedwith 100 ng/ml
LPS for 24 h and then exposed to either solvent (ethanol, 0.1% ﬁnal
concentration) or 10 nM 1α,25(OH)2D3 (kindly provided by Milan
Uskokovic, Bioxell Inc, Nutley, NJ, USA). For ChIP assays THP-1 cells
were ﬁrst treated with LPS as above, then with 2.5 μM α-amanitin
(Sigma-Aldrich) for 2 h, after which it was removed, followed by
exposure to 1α,25(OH)2D3. For mRNA stability studies THP-1 cells
were ﬁrst treated with LPS as above, after which 1 μg/ml actinomycin
D (Sigma-Aldrich) was added.
2.2. Human monocyte isolation
To obtain pure primary monocyte preparations from buffy coats
(provided by the Red Cross, Luxembourg), ﬁrst peripheral blood
mononuclear cells (PBMCs) were isolated by density gradient
centrifugation using Ficoll–Paque Plus (GE Healthcare, Diegem,
Belgium) and Leucosep tubes (Greiner bio-one, Wemmel, Belgium).
The layer containing PBMC and platelets was collected and washed
twice withMACS buffer. The number of PBMCwas determined using a
hemacytometer. Then, CD14+ cells are magnetically labeled with
colloidal superparamagnetic CD14 MicroBeads (Miltenyi Biotech,
Utrecht, The Netherlands), which are conjugated with monoclonal
anti-human CD14 antibodies, according to the manufacturer's
protocol. Brieﬂy, after incubation of cells and microbeads (15 min at4 °C), cells were washed with MACS buffer (PBS pH 7.2, 2 mM EDTA,
0.5% (w/v) BSA) and resuspended. The cell suspension was loaded
onto a MACS LS separation column (Miltenyi Biotech, Utrecht, The
Netherlands) in a magnetic ﬁeld. Thus, only magnetically labeled
CD14+ cells were retained in the column and were eluted with MACS
buffer from the column after washing and removal of the column from
the magnetic ﬁeld. The purity of the CD14+ cells was evaluated by
ﬂow cytometry using anti-CD14-FITC and anti-IgG2a-FITC antibodies
(ImmunoTools) and a FACSCantoII Flow Cytometry System (Becton
Dickinson). The number of the primary monocytes was determined
using a hemacytometer. Then, the cells were pelleted and resus-
pended in prewarmed RPMI-1640medium (Lonza, Verviers, Belgium)
containing 10% FBS, 2 mM L-glutamine, 0.1 mg/ml streptomycin, and
100 U/ml penicillin to a density of 0.8–1×106 cells/ml and incubated
overnight in a humidiﬁed 95% air/5% CO2 incubator. Then, ligand
treatments were performed followed by total RNA extraction.
2.3. Total RNA extraction, cDNA synthesis, and real-time quantitative
PCR
Total RNA was extracted using High Pure RNA Isolation Kit (Roche
Diagnostics, Mannheim, Germany) and cDNA synthesis was performed
using Transcriptor High Fidelity cDNA Synthesis Kit (Roche) according
to the manufacturer's instructions. Real-time quantitative PCR was
performed with a LightCycler 480 apparatus (Roche) using TaqMan
Gene ExpressionAssays (Applied Biosystems, Carlsbad, CA, USA) for IL-10
(Hs00174086_m1), IL-12B (Hs00233688_m1), TLR-4 (Hs00152939_m1)
and RPLP0 (4333761F) and Maxima™ Probe qPCR Master Mix (Fer-
mentas, Vilnius, Lithuania). PCR cycling conditions were: 10 min at 95 °C,
followed by 50 cycles of 15 s at 95 °C and 60 s at 60 °C. Fold changeswere
calculated using the formula 2−(ΔΔCt), where ΔΔCt=ΔCt(1α,25(OH)2D3)−
ΔCt(EtOH), and ΔCt=Ct(target gene)−Ct(RPLP0). Ct is the cycle at which the
threshold line is crossed. For statistical analysis, fold changes were log2-
transformed and two-tailed Student's t-tests were performed to calculate
statistical signiﬁcance between solvent treated and ligand treated
samples.
2.4. siRNA silencing
THP-1 cells were transfected with either non-speciﬁc siRNA
oligomers or Stealth™ siRNAs targeting the VDR mRNA (Invitrogen,
Carlsbad, CA, USA) by using RNAiMAX reagent (Invitrogen) according
to the manufacturer's instructions. The cells were seeded into 6-well
plates and grown in phenol red-free DMEM supplemented with 5%
charcoal-stripped FBS. Liposomes containing control or VDR siRNA
were formed by incubating 100 pmol of each siRNA duplex with 5 μl
of RNAiMAX for 20 min at room temperature in a total volume of
500 μl of phenol red-free DMEM without antibiotics. The liposomes
were added to the cells and siRNA treatment was continued for 48 h,
then the cells were treated with 100 ng/ml LPS for 24 h and ﬁnally
exposed to either solvent (ethanol, 0.1% ﬁnal concentration) or 10 nM
1α,25(OH)2D3 for indicated time periods. Silencing of VDR at the
protein level was veriﬁed by Western blotting using 25 μg of whole-
cell extract from THP-1 cells and anti-VDR antibody (sc-1008, Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Cellular proteins were
separated using 12% SDS polyacrylamide gel electrophoresis. The
blotted proteins were detected by using IR800 ﬂuorescence labeled
secondary antibodies (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
and Odyssey reader (Li-Cor Biosciences, Lincoln, NE, USA).
2.5. Gel shift assay
VDR, RXR, and VDIR proteins were generated by coupled in vitro
transcription/translation reaction using full-length cDNAs subcloned
into the T7/SV40 promoter-driven pSG5 expression vector (Strata-
gene, LaJolla, CA, USA) and TNT Quick Coupled Transcription/
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(Promega, Madison, WI, USA). Oligonucleotides were labeled with
Klenow fragment DNA polymerase (Fermentas) in the presence of a
nucleotide mixture containing 32P α-dCTP. In gel shift assays, 100 ng
of the appropriate in vitro translated proteins was incubated for
15 min in a total volume of 20 μl of binding buffer (10 mM Hepes, pH
7.9, 150 mM KCl, 1 mM dithiothreitol, 0.2 μg/μl of poly(dI–C), 5%
glycerol). 32P-labeled double-stranded oligonucleotides
corresponding one VDRE were then added and incubation was
continued at room temperature for 20 min. Protein–DNA complexes
were resolved by electrophoresis through non-denaturing 5% (w/v)
polyacrylamide gels in 0.5×TBE (45 mM Tris, 45 mM boric acid, and
1 mM EDTA, pH 8.3) and quantiﬁed on an FLA-3000 reader (Fuji,
Tokyo, Japan) using Image Gauge software (Fuji).
2.6. Cell transfections and luciferase reporter gene assays
Human colon adenocarcinoma SW-480 cells were transfectedwith
the pGL4 containing minimal promoter of thymidine kinase (tk) gene
and the upstream region of the human IL-10 gene including ER7 and
ER8 elements. A construct containing proximal promoter of human
CYP24 gene with a cluster of DR3-type VDREs was used as a positive
control. SW-480 cells were treated with 100 ng/ml LPS for 24 h prior
to transfection. The DOTAP transfection protocol was used with a
mixture of 1 μg of different reporter constructs and 1 μg of expression
vector for human VDR gene (pSG5-hVDR) in a 6-well plate format.
After 5 h, 1α,25(OH)2D3 was added to 100 nM and luciferase reporter
assay was performed 16 h post-treatment with BriteLite luciferase
substrate (Perkin Elmer, Waltham, MA, USA) in a Victor3 multilabel
counter (Perkin Elmer) equipped with automatic dispenser. Lucifer-
ase activities were normalized with respect to total protein
concentration.
2.7. Targeting of putative VDREs by duplex RNAs
The siRNA molecules for enhancer targeting were designed by
Dharmagon siDESIGN Center algorithm (www.dharmacon.com/
DesignCenter/DesignCenterPage.aspx) to cover either one or both
half sites of the consensus sequences of ER7 and ER8-type elements
and obtained from Thermo Fisher (for sequences see Table S1). The
Stealth RNAi™ siRNA Negative Control Med GC (Invitrogen) was used
as a control. THP-1 cells (2.5×105 cells) were plated on a 24-well
plate immediately prior to transfection in phenol red-free DMEM
supplemented with 5% charcoal-stripped FBS, 2 mM glutamine,
0.1 mg/ml streptomycin and 100 U/ml penicillin. 4 μl TransIT-TKO
Transfection Reagent (Mirus Bio LCC, Madison, WI) was diluted with
50 μl serum-free DMEM and incubated for 20 min at room temper-
ature. siRNA molecules (40 nM ﬁnal concentration) were added and
the incubationwas continued for 20 min at room temperature and the
mixture was added dropwise to the cells. Phenol red-free DMEM
supplemented with 5% charcoal-stripped FBS, 2 mM glutamine,
0.1 mg/ml streptomycin, and 100 U/ml penicillin was added 6 h
after transfection and 24 h after transfection the cells were treated
with 100 ng/ml LPS for 24 h after which the cells were exposed to
either solvent (ethanol, 0.1% ﬁnal concentration) or to 10 nM 1α,25
(OH)2D3. After indicated periods of time, total RNA was extracted and
RT-PCR was performed as described previously. Viability of the cells
was determined using AlamarBlue reagent according to the instruc-
tions of the manufacturer (Invitrogen).
2.8. ChIP assays
ChIP was performed with LPS-treated THP-1 cells as previously
described [29] with few modiﬁcations. Brieﬂy, nuclear proteins were
cross-linked to DNA by adding formaldehyde for 10 min. Cross-linking
was stoppedwith glycine at room temperature for 5 min. Themediumwas removed and the cells were washed twice with ice-cold PBS. The
cells were collected and resuspended in lysis buffer containing
protease inhibitors. The chromatin was fragmented by sonication
and non-speciﬁc backgroundwas removed using salmon spermDNA/
protein A agarose slurry (Millipore, Temecula, CA, USA) at 4 °C for 1 h.
The recovered chromatin solutions were diluted 1:10 (v/v) in ChIP
dilution buffer and incubated with 1 μg of indicated antibodies at 4 °C
overnight. Non-speciﬁc IgG (12-370) and antibodies against H3K9
acetylated at K9 and K14 (H3Ac, 06-599) and dimethylated H3K9 (07-
521) were from Upstate Biotechnology (Lake Placid, NY, USA), the
antibodies against the C-terminus of histone H3 (07-690) and
dimethylated H3K4 (07-030) from Millipore, the antibodies against
VDR (sc-1008) and RXRα (sc-553) from Santa Cruz Biotechnology and
the antibody against NCoR (ab24552) from Abcam (Cambridge, UK).
The immunocomplexes were collected using protein A agarose slurry
(Millipore) and reverse cross-linked in the presence of 2 μl of
proteinase K (18.9–20.1 mg/ml) (Fermentas) at 64 °C overnight,
after which phenol:chloroform extraction and ethanol precipitation
were performed. ChIP samples were analyzed with quantitative PCR
using BHQ1-FAM6 hydrolysis probes (Eurogentec, Liege, Belgium)
and Maxima™ Probe qPCR Master Mix. The sequences of the primers
and the hydrolysis probes are listed in Tables S2 and S3, respectively.
The qPCR reaction was performed with a LightCycler 480 apparatus
using the same PCR proﬁle as with cDNA samples in an appropriate
annealing temperature. The results were normalized with respect
to input. Non-speciﬁc IgG results were subtracted by using the
formula 2−(ΔCt)⁎100(speciﬁc antibody)−2−(ΔCt)⁎100(non-speciﬁc IgG),
where ΔCt is Ct(immunoprecipitated DNA)−Ct(input) and Ct is the cycle at
which the threshold line is crossed. Two-tailed Student's t-tests were
performed and statistical signiﬁcance of the percents of inputs was
calculated in reference to time point 0 min.
2.9. Micrococcus nuclease (MNase) assay
Chromatin was fragmented at mono-nucleosome level by MNase
digestion using themethod described by Soutoglou and Talianidis [30]
with slight modiﬁcations. Prior to the MNase digestion, THP-1 cells
(106 cells) were washed twice with PBS and suspended to 1 ml of lysis
buffer (10 mM Tris, pH 7.4, 10 mMNaCl, 5 mMMgCl2, 0.1% NP40) and
incubated on ice for 10 min. The nuclei were collected by centrifuga-
tion (1500×g, 5 min) and washed once with lysis buffer. The nuclei
were suspended toMNase reaction buffer (50 mMTris, pH 7.5, 15 mM
NaCl, 3 mM MgCl2, 5 mM KCl, 1 mM CaCl2, protease inhibitors) and
30 U of MNase (Fermentas) was added. After a 1 h incubation at 37 °C,
2 μl of proteinase K was added and the samples were incubated at
64 °C overnight. Finally, DNA was recovered by phenol–chloroform
extraction followed by ethanol precipitation, and analyzed by
quantitative PCR using primers listed in Tables S4 and S5 and
Maxima™ SYBR Green qPCR Master Mix (Fermentas). PCR cycling
conditionswere: 10 min at 95 °C, followed by 50 cycles of 20 s at 95 °C,
20 s at appropriate annealing temperature, and 20 s at 72 °C, ending
with 10 min at 72 °C. The resultswere normalizedwith respect to non-
digested DNA (input) by using the formula 2−(ΔCt)⁎100, where ΔCt is
Ct(MNase-digested DNA)−Ct(input) and Ct is the cycle at which the
threshold line is crossed. Two-tailed Student's t-tests were performed
and statistical signiﬁcance of the percents of inputs was calculated in
reference to time point 0 min.
2.10. Chromosome conformation capture assay
8×106 THP-1 cells were treated with LPS and 1α,25(OH)2D3, after
which the cells were collected as described for ChIP analysis, with the
exception of the cross-linking time (20 min). The samples were
resuspended in 100 μl lysis buffer and sonicated for one 30 s cycle.
25 μl aliquots of the lysate were separated as +ligase and −ligase
samples. ChIP dilution buffer, protease inhibitors, 2×Tango buffer
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volume of 100 μl, after which the samples were incubated at 37 °C
overnight. After that 10 μl 10% Triton X-100 (Sigma-Aldrich) was
added and the samples were incubated at 37 °C for 1 h. To −ligase
samples 500 μl H2O and 2 μl proteinase K were added and the samples
were incubated at 64 °C overnight. Before proteinase K treatment +
ligase samples were incubated 3 h at room temperature in the
presence of T4 ligase buffer (Fermentas), 0.5 mM ATP and 15 U T4
ligase (Fermentas) in a total volume of 600 μl. In the end phenol:
chloroform extraction and ethanol precipitation were performed. The
recovered DNA was analyzed by PCR using primers listed in Table S6
and Maxima™ SYBR Green qPCR Master Mix, after which the PCR
products were separated on 2% agarose gel. PCR cycling conditions
were the same as with MNase samples.Fig. 1. Expression proﬁling of the human IL-10 gene. Relative mRNA expression of IL-10wasm
(B) for indicated time periods after stimulation with 10 nM 1α,25(OH)2D3. (C) siRNA silenc
from LPS-treated THP-1 cells. (D) Relative mRNA expression of IL-10 was measured after 6
was studied by treating the cells with 1 μg/ml actinomycin D prior to RNA extraction. The res
performed to calculate p-values in reference to vehicle treatment (*pb0.05, **pb0.01, ***p3. Results
3.1. IL-10 is a down-regulated primary VDR target gene
LPS-treated human acute monocytic leukemia THP-1 cells serve
throughout this study as a model system for human macrophages.
Prior to treatment with 1α,25(OH)2D3 the cells were treated for 24 h
with LPS. Quantitative PCR using TaqMan probes showed that this
increased the basal expression of IL-10 2.9-fold (Fig. S1). The effect of
1α,25(OH)2D3 on IL-10 expressionwasmeasured for 8 h every 15 min
and after 24 h and 48 h (Fig. 1A). IL-10 mRNA expression started to
decrease 90 min after onset of ligand treatment and reached with 36%
of basal expression the lowest level after 255–270 min (Fig. 1A). At
time point 300 min IL-10 mRNA expression turned back to basaleasured by quantitative PCR in LPS-treated THP-1 cells (A) and primarymonocytic cells
ing of VDR at protein level was veriﬁed by Western blotting using whole-cell extracts
h of 10 nM 1α,25(OH)2D3 treatment after silencing of VDR. (E) Stability of IL-10 mRNA
ults were normalized to the housekeeping gene RPLP0. Two-tailed Student's t-tests were
b0.001). In each panel, n is at least 3. Error bars indicate S.D.
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for another 3 h. At time point 24 h IL-10 mRNA expression had
returned to basal levels, while at time point 48 h it had increased 3-
fold. For comparison we examined the effect of 1α,25(OH)2D3 on IL-
10 expression also in primary human monocytes. According to our
data, the ligand effect was not as clear as in THP-1 cells, since at time
point 2 h no repression could be observed and at time point 4 h only
minor repression was visible. However, at time point 6 h a signiﬁcant
1.6-fold repression and at 24 h a 2.3-fold induction could be observed
(Fig. 1B). Please note that the primary cells were not pre-treated with
LPS.
In order to conﬁrm that the observed repression of IL-10was VDR-
dependent, we silenced the VDR gene using siRNA. The efﬁciency of
VDR silencing at the protein level was veriﬁed by Western blotting
using whole-cell extracts (Fig. 1C). 6 h after 1α,25(OH)2D3 stimula-
tion in the presence of VDR speciﬁc siRNA, no IL-10 repression was
observed, while non-speciﬁc siRNA did not affect to the repressiveFig. 2. Functionality of ER7- and ER8-type VDREs at the IL-10 promoter. (A) Gel shift analysis
type VDREs in the presence and absence of 1α,25(OH)2D3. A DR4-type element from the rat
protein-complexed DNA was quantiﬁed using a Fuji FLA-3000 reader. NS indicates non-spec
elements was cloned in front of thymidine kinase (tk) promoter driving the luciferase (Luc) g
VDREs was used as a positive control and the empty reporter vector as a negative control. Luc
treatment. Columns indicate the means of three independent experiments and the tips of t
calculate p-values in reference to solvent treated samples (*pb0.05, **pb0.01, ***pb0.001)effect of the VDR ligand (Fig. 1D). The stability of IL-10 mRNA was
determined by treating LPS-stimulated THP-1 cells with actinomycin
D (Fig. 1E). The half-life of the IL-10 mRNA was found to be 0.9 h,
which is in agreement with the repression observed in the time-
course experiments.
Taken together, our data suggest that IL-10 is a primary VDR target
gene, which is initially down-regulated and later after 24 h up-
regulated.
3.2. Putative VDREs within the IL-10 gene
In order to locate the genomic regions within the human IL-10
gene that associate with VDR, we performed a ChIP scanning analysis
using anti-VDR antibody (Fig. S2). From the 27 genomic regions
spanning over the region from−10037 to +1862 relative to the IL-10
TSS ten recruited VDR ligand-dependently. Regions 12, 19 and 22
located at repetitive sequences and regions 14 and 17 did not containwas used to study the ability of in vitro translated VDR and RXR to bind to ER7- and ER8-
Pit-1 served as a positive control. Representative gels are shown. (B) The percentage of
iﬁc complexes. (C) The upstream region of the human IL-10 gene including ER7 and ER8
ene. The proximal promoter of the human CYP24 gene containing a cluster of DR3-type
iferase activity was determined from LPS-treated SW480 cells after a 16 h 1α,25(OH)2D3
he bars represent standard deviations. Two-tailed Student's t-tests were performed to
. In each bar, n is at least 3. Error bars indicate S.D.
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were therefore not further investigated. Region 5 (+99 to −134)
contained the TSS and therefore it was not surprising to ﬁnd VDR
there due to looping effects from other regions. An in silico screening
using the net-based program RESearch [32] revealed that region 2
(+1433 to +1006) contains E-box elements, where VDR may bind
backpack on VDIR, and that region 9 (−1432 to −1986) contained
ER7- and ER8-type VDREs for direct binding of VDR (Fig. S2). We
assume that the observed recruitment of VDR to the regions 1 and 10
resulted in ﬂanking effect from regions 2 and 9, respectively. A
conservation analysis based on 28 species by PhyloP [33] as well as
manual sequence comparison between human, mouse and dog
suggested that the genomic regions containing the above putative
VDREs and E-box elements were conserved across different species
(Fig. S2).
3.3. Functionality of the putative VDREs
The potential of the putative regulative regions to associate with in
vitro translated VDR and RXR was examined using gel shift analysis.
The ER7-type VDRE (−1502 to −1484) and the ER8-type VDRE
(−1721 to −1701) were able to bind VDR–RXR heterodimer
complexes, but less prominent than the established DR4-type VDRE
of the rat Pit-1 gene (gaAGTTCAtgagAGTTCA) [34]. Interestingly, the
ER8 type VDRE of the IL-10 gene aswell as the control VDRE showed in
the presence of 1α,25(OH)2D3 more prominent VDR–RXR hetero-
dimer binding than in its absence (Fig. 2A and B). Compared with the
control negative VDRE (nVDRE) of the human CYP27B1 gene
(ccattaaccCACCTGcCATCTGcc) [12], the E-box type elements
(+1079 to +1097) did not show direct binding of VDR–RXR
heterodimers and associated only weakly with VDIR (Fig. S3A).
The functionality of the putative VDREs was examined by reporter
gene assays (Fig. 2C). The reporter construct containing the proximal
promoter of human CYP24 gene was 13-fold inducible by 1α,25
(OH)2D3. In contrast, the basal activity of the IL-10 construct was
reduced by 25% by 1α,25(OH)2D3 treatment. The construct containing
E-box type elements showed less response to stimulation with 1α,25
(OH)2D3 than the ER7- and ER8-type elements (Fig. S3B).
In summary, within 12 kb of the IL-10 gene we identiﬁed at
positions −1500 to −1700 two VDR–RXR heterodimer binding
VDREs and at position +1000 an E-box sequence associating with
VDIR.
3.4. The distal VDREs loop to the TSS
For proving the functionality of the promoter region containing
the ER7- and ER8-type VDREs, we used 3C analysis [35] and
investigated the chromatin looping between the region of the
VDREs and the TSS of the IL-10 gene (Fig. 3). The results suggest
that the VDRE region can loop to the TSS in a ligand- and time-
dependent fashion, since the distal promoter region was connected
with the TSS at time points 10–20 min, 50 min and 80–90 min after
onset of ligand treatment. In contrast, the control regions or the region
of the E-box elements showed no interaction with the TSS. Taken
together, 1α,25(OH)2D3 speciﬁcally induces looping between the
distal promoter region and the TSS. Therefore, we focused further
investigations on this region.
3.5. IL-10 repression by 1α,25(OH)2D3 is mediated via ER8-type element
In order to determine if one or both distal elements participate to
the 1α,25(OH)2D3-dependent regulation of IL-10 expression, we
applied the recently reportedmethod of promoter targeting by duplex
RNAs [36,37]. We reasoned that targeting of the putative VDREs
would prevent the observed ligand effects assuming that the elements
were functional. According to our results, targeting of the ER7-typeelement did not show signiﬁcant effect on 1α,25(OH)2D3-dependent
repression of IL-10 mRNA expression at early time points 2 and 4 h
(Fig. 4). Instead, targeting of the ER8-type element prevented the
repression and even lead to signiﬁcant induction of IL-10, suggesting
that the primary effects of 1α,25(OH)2D3 are mediated via the ER8-
type element. Interestingly, both ER7 and ER8 appeared to participate
to the 1α,25(OH)2D3-dependent up-regulation of IL-10 expression,
since targeting of any of the two elements prevented the ligand effect
after a 48 h hormone treatment. To verify that the observed targeting
effects were speciﬁc to the IL-10 expression, we repeated the RT-PCR
analysis with IL-12B and TLR-4 genes, that are known to be repressed
by 1α,25(OH)2D3 [2,38]. Our data showed that neither targeting with
non-speciﬁc siRNA nor ER7 or ER8 speciﬁc siRNAs affected to the
ligand-dependent repression of above genes. The viability studies
showed that both non-speciﬁc siRNA and speciﬁc siRNA treatments
clearly decreased the cell's viability in a treatment–time-dependent
fashion (Fig. S5). However, it is notable that the viability was similar
after all treatments. Thus, the observed promoter targeting results
were reliable.3.6. VDR, RXR and NCoR associate cyclically with the promoter and the
TSS regions
The periodic looping between the VDRE containing promoter
region and the TSS suggests that this region may recruit VDR in a
cyclical fashion and that via looping VDR may also be detectable on
the TSS. Therefore, we used time-resolved quantitative ChIP analysis
(every 10 min over 100 min) and measured the recruitment of VDR,
RXR and the co-repressor NCoR to the promoter and the TSS regions
(Fig. 5). VDR associated with both the promoter region and the TSS at
time points 10 and 50 min after onset of ligand treatment (Fig. 5A).
The recruitment of RXR to the TSS followed that of VDR, while it
associatedwith the promoter regionmore evenly andwas only absent
at time point 40 min (Fig. 5B). Also NCoR bound to the promoter
region rather evenly, but was enriched on the TSS at time points 20, 50
and 70 min (Fig. 5C).
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Fig. 4. Targeting of the ER7- and ER8-type VDREs by duplex RNAs. THP-1 cells, which
had been pre-treated for 24 h with 100 ng/ml LPS, were transfected with control siRNA
or ER7 or ER8 speciﬁc siRNAs. After 24 h the cells were exposed to either solvent
(ethanol, 0.1% ﬁnal concentration) or to 10 nM 1α,25(OH)2D3. After the indicated
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Fig. 5. Ligand treatment leads to cyclical recruitment of transcription factors to the IL-10
promoter. ChIP assays were performed using antibodies against VDR (A), RXR (B) and
NCoR (C) with 10 min intervals of 10 nM 1α,25(OH)2D3 treatment up to 100 min in
LPS-treated THP-1 cells. The IL-10 TSS is indicated in black and the VDRE region in red.
Two-tailed Student's t-tests were performed to calculate p-values in reference to time
point 0 (*pb0.05, **pb0.01, ***pb0.001). In each panel, n is at least 3. Error bars
indicate S.D.
1282 J.M. Matilainen et al. / Biochimica et Biophysica Acta 1803 (2010) 1276–1286In summary, VDR shows a clear cyclical association both with the
promoter region and the TSS with a periodicity of 40 min, while RXR
and NCoR demonstrate signiﬁcant peaks of association only with the
TSS.
3.7. Ligand-dependent epigenetic changes at the promoter and TSS
regions
In order to monitor changes of chromatin activity related to the
1α,25(OH)2D3-dependent repression of IL-10 transcription, we
performed quantitative ChIP analysis with antibodies against acety-
lated or methylated histone H3 (Fig. 6). As for VDR, RXR and NCoR
binding (Fig. 5), the changes in the chromatin status were assessed
every 10 min up to 100 min after onset of ligand treatment. In theabsence of ligand both the promoter region and the TSS showed
histone H3 acetylation (H3ac), which was lost at time points 50 and
80 min, but was maximal at 60–70 min (Fig. 6A). In the absence of
ligand dimethylation of histone H3 at K9 (H3K9me2), a marker for
inactive chromatin, was not detectable both at the promoter region
and the TSS (Fig. 6B). After ligand treatment the H3K9me2 levels
peaked at the promoter region at time points 10, 50 and 90 min. At the
TSS region the H3K9me2 levels were also maximal at time point
10 min, but stayed high also in the period of 40–90 min.
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Fig. 6. Ligand-dependent epigenetic changes at the IL-10 promoter and the TSS. ChIP
assays were performed using antibodies against H3ac (A) and H3K9me2 (B) with
10 min intervals of 10 nM 1α,25(OH)2D3 treatment up to 100 min in LPS-treated THP-1
cells. The IL-10 TSS is indicated in black and the VDRE region in red. Two-tailed
Student's t-tests were performed to calculate p-values in reference to time point 0
(*pb0.05, **pb0.01, ***pb0.001). In each panel, n is at least 3. Error bars indicate S.D.
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on inactive chromatin (H3K9me2) the promoter region and the TSS
showed a cyclical behavior with a periodicity of 30–50 min between
the minima and maxima.
3.8. Ligand-dependent chromatin remodeling at the promoter and TSS
regions
In order to investigate, whether the periodic appearance of
repressive histone marks result in condensation of the chromatin,
we performed limited MNase digestion assays (Fig. 7). The changes in
the chromatin status were assessed every 10 min over a period of
100 min after onset of ligand treatment. A schematic presentation in
Fig. 7A illustrates the possible locations of the nucleosomes that
would protect the chromatin within the studied amplicons against
digestion by MNase. The efﬁciency of MNase digestion was conﬁrmed
by agarose gel electrophoresis to ensure that the chosen digestion
time resulted in chromatin fragments in a mono-nucleosome
(b200 bp) size (Fig. 7B). The nucleosome density increased ligand-
dependently at all four studied regions. On regions a and b (around
the ER8-type VDRE) nucleosome enrichment was maximal at time
points 20–30 min and 60–80 min (Fig. 7C and D). The nucleosome
enrichment around the ER7-type VDRE (at regions c and d) wasclearly different, as the highest enrichment could be observed at time
points 50–80 min at region c and at 70–90 min at region d (Fig. 7E and
F). Thus, our data suggest that chromatin remodeling follows the
cyclic histone modiﬁcations with a 10–20 min delay. The ﬁrst
repressive cycle appears to increase the nucleosome density only at
the ER8-type VDRE, but the second repressive cycle results in more
general condensation of the chromatin, since increased nucleosome
density could be observed at both VDREs as well as at the TSS (Fig. S4).
In summary, the nucleosome density assay could conﬁrm the
results of the ChIP assays concerning the periodic changes of
chromatin activity at the promoter region and the TSS.
4. Discussion
IL-10 is a cytokine that showsmainly suppressive effects on innate
immunity, but has also stimulatory effects on adaptive immunity. The
critical role of IL-10 is underlined by the fact that it is expressed
ubiquitously among innate and adaptive immune cells including
monocytes, macrophages, dendritic cells, B cells, CD8+ and regulatory
T cells, TH1, TH2 and TH17 cells [39]. IL-10 limits the ability of antigen
presenting cells to promote the differentiation and proliferation
of CD4+ T cells and therefore affects to both initiation and progress of
adaptive T cell responses. In addition, IL-10 inhibits the expression of
a number of pro-inﬂammatory cytokines and thus further suppresses
the ability of effector T cells to prolong the inﬂammatory responses
[40,41].
Several studies showed that IL-10 expression is induced by 1α,25
(OH)2D3 in different cells of the immune system mediating in this
way the known immunosuppressive effects of 1α,25(OH)2D3 [25–
28]. However, opposite effects of 1α,25(OH)2D3 on the production of
IL-10 both in vitro and in vivo have also been reported [22–24,42,43].
The contrary ligand effects on IL-10 expression may be due to
different cell types being studied, but interestingly, the reports
describing up-regulation of IL-10 expression seem to be related to
treatments with 1α,25(OH)2D3 for several days, whereas reports on
IL-10 down-regulation by VDR ligands use shorter stimulation times.
This let us hypothesize that 1α,25(OH)2D3-dependent regulation of
IL-10 expression could be bidirectional depending on the time of
measurement.
In this study we showed a clear, ligand-dependent repression of
IL-10mRNAwithin the ﬁrst 8 h of ligand treatment, whereas after 48 h
a 3-fold induction was observed. Highly similar ligand effect could be
observed also in primarymonocytes. Thus, the primary effect of 1α,25
(OH)2D3 on the expressionof IL-10 is repression,which is later overrun
by an up-regulating secondary effect. This may explain in part the
physiological role of 1α,25(OH)2D3 in the regulation of adaptive
immune response. The initial down-regulation of IL-10 immediately
after infection would ensure an effective immune response, since low
IL-10 levels allow the production of pro-inﬂammatory cytokines in
higher quantities. The delayed, secondary effects that result in up-
regulation of IL-10 by 1α,25(OH)2D3 then suppress the innate immune
response in order to avoid effects of long-lasting inﬂammation, such as
tissue damage.
An absolute requirement for direct transcriptional regulation of
any gene by 1α,25(OH)2D3 is that the TSS of the respective gene is
connected to at least one genomic region containing positive or
negative VDREs. Our 3C results suggest that only the promoter region
containing an ER7- and an ER8-type VDRE (at positions −1700 to
−1500) loops to the TSS. In addition, this region was able to
signiﬁcantly repress the luciferase activity in reporter gene analysis.
These data indicate that one or both of the above VDREs is responsible
for the 1α,25(OH)2D3-dependent repression of IL-10 expression. Our
observations agree with the data of Tavera-Mendoza et al., who
reported that in human SCC25 head and neck squamous cell
carcinoma cells VDR ligand-dependently associates with a region of
an ER8-type VDRE (−1791 to −1464) of the IL-10 gene [44].
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regulation of IL-10 expression, we utilized promoter targeting by
duplex RNAs [36,37]. According to our results, the ER8-type VDRE is
critical for short-term repression and both ER7 and ER8 elements are
needed for up-regulation after longer exposure to the hormone. These
data suggest that the VDREs are used differently during different
hormone exposure times. This can be due to changes in the cell's
proteome in response to hormone treatment [45].
It has been recently reported that the transcriptional activation of
some nuclear receptor target genes involves cyclic association of
transcription factors and their co-regulators to the regulatory regions
of the respective genes and that this periodicity reﬂects also to the
mRNA expression levels [10,12]. However, the available data concerns
exclusively up-regulated genes. Moreover, until now the mechanisms
of transcriptional repression is not sufﬁciently known. Therefore, we
used the primary down-regulating effects of 1α,25(OH)2D3 on IL-10
expression as a model for examining the effects of transcription factorcycling on gene repression.We found that the repressive transcription
factor complex associates in a ligand- and time-depend fashion both
with the TSS and the promoter region containing the VDREs. This
caused periodic epigenetic changes and chromatin remodeling on
both chromatin regions.
Since there are no VDR binding sites in vicinity of the TSS [31], we
assume that the observed association of the repressive complex with
the TSS results from the looping of the VDRE region to the TSS as
observed in our 3C assays. This suggests that the mechanisms of
transcriptional activation and repression share common features of
cyclic association of transcription factors and that they both involve
changes in higher order chromatin hierarchy. However, in contrast to
up-regulated genes, such as CYP24 and CDKN1A [10,12], no clear
periodicity in the repression of IL-10 mRNA could be detected.
Therefore, at least in the case of the IL-10 gene, the cyclical association
of transcription factors does not reﬂect to the mRNA expression level.
The reason for this is most likely an insufﬁcient degradation of IL-10
1285J.M. Matilainen et al. / Biochimica et Biophysica Acta 1803 (2010) 1276–1286mRNA during one transcriptional cycle and the involvement of
activating transcriptions factors, which have not been characterized
in this study. In addition, to see the cycling also at mRNA level would
require that the mRNA synthesis would happen relatively fast. This
may not be the case in the LPS induced IL-10 mRNA synthesis that is
mediated via cell surface receptor TLR-4.
In conclusion, this study indicates that in LPS-treated THP-1 cells
the primary effect of 1α,25(OH)2D3 on IL-10 expression is repression,
which occurs during the ﬁrst hours after onset of ligand treatment.
We propose that this repression occurs in order to ensure an efﬁcient
immune response against microbial infections. We found that the
1α,25(OH)2D3-dependent repression is achieved through cyclic
recruitment of VDR to ER7- and ER8-type VDREs within a promoter
region of the IL-10 gene. Thus, both in transcriptional activation and
repression cyclic association of transcription factors is involved.
However, at least for the IL-10 gene, the cycling of transcription
factors and chromatin marks does not translate to changes in mRNA
expression levels.
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